biote (BTMD) Competitors $3.22 +0.20 (+6.62%) Closing price 04:00 PM EasternExtended Trading$3.22 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. DAWN, AUTL, KALV, AVBP, DNTH, VIR, ANAB, TSHA, ORGO, and TBPHShould you be buying biote stock or one of its competitors? The main competitors of biote include Day One Biopharmaceuticals (DAWN), Autolus Therapeutics (AUTL), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Dianthus Therapeutics (DNTH), Vir Biotechnology (VIR), AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Day One Biopharmaceuticals Autolus Therapeutics KalVista Pharmaceuticals ArriVent BioPharma Dianthus Therapeutics Vir Biotechnology AnaptysBio Taysha Gene Therapies Organogenesis Theravance Biopharma Day One Biopharmaceuticals (NASDAQ:DAWN) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher valuation and earnings, DAWN or BTMD? biote has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.62-$95.50M-$0.95-7.58biote$197.19M0.81$3.16M$0.903.58 Is DAWN or BTMD more profitable? biote has a net margin of 15.73% compared to Day One Biopharmaceuticals' net margin of -50.63%. Day One Biopharmaceuticals' return on equity of -19.01% beat biote's return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-50.63% -19.01% -16.99% biote 15.73%-21.00%18.26% Does the media refer more to DAWN or BTMD? In the previous week, Day One Biopharmaceuticals had 12 more articles in the media than biote. MarketBeat recorded 12 mentions for Day One Biopharmaceuticals and 0 mentions for biote. Day One Biopharmaceuticals' average media sentiment score of 0.55 beat biote's score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Day One Biopharmaceuticals Positive biote Neutral Do analysts recommend DAWN or BTMD? Day One Biopharmaceuticals currently has a consensus price target of $25.29, suggesting a potential upside of 251.19%. biote has a consensus price target of $6.00, suggesting a potential upside of 86.34%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Day One Biopharmaceuticals is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13biote 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals hold more shares of DAWN or BTMD? 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 24.0% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, DAWN or BTMD? Day One Biopharmaceuticals has a beta of -1.26, meaning that its share price is 226% less volatile than the S&P 500. Comparatively, biote has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. SummaryDay One Biopharmaceuticals beats biote on 9 of the 17 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.30M$10.84B$5.76B$9.59BDividend YieldN/A1.87%4.41%4.09%P/E Ratio3.5820.9031.1026.05Price / Sales0.8129.66470.24120.75Price / Cash3.9424.5537.7358.48Price / Book-2.033.519.536.61Net Income$3.16M$211.77M$3.26B$265.56M7 Day Performance10.27%4.44%2.11%1.98%1 Month Performance-21.84%10.98%5.12%1.33%1 Year Performance-44.00%-8.36%31.25%21.15% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.2981 of 5 stars$3.22+6.6%$6.00+86.3%-47.5%$149.30M$197.19M3.58194DAWNDay One Biopharmaceuticals2.5233 of 5 stars$5.90-3.3%$25.33+329.4%-50.8%$624.84M$131.16M-6.2160News CoverageInsider TradeAUTLAutolus Therapeutics3.127 of 5 stars$2.47+6.0%$9.32+277.3%-57.1%$620.11M$10.12M-2.81330Gap UpKALVKalVista Pharmaceuticals4.0422 of 5 stars$12.51+0.8%$26.29+110.1%+3.0%$619.93MN/A-3.39100AVBPArriVent BioPharma2.5211 of 5 stars$17.42-3.2%$39.29+125.5%-16.9%$615.48MN/A-4.6240High Trading VolumeDNTHDianthus Therapeutics1.0932 of 5 stars$18.89+0.7%$53.00+180.6%-17.1%$603.32M$6.24M-5.8180Analyst ForecastVIRVir Biotechnology3.4551 of 5 stars$4.28-0.5%$30.25+606.8%-49.5%$597.34M$74.21M-1.07580Positive NewsANABAnaptysBio3.0557 of 5 stars$20.00-4.9%$47.75+138.8%-46.1%$588.78M$91.28M-4.46100TSHATaysha Gene Therapies3.4307 of 5 stars$2.76+1.5%$8.17+195.9%+27.0%$583.88M$8.33M-8.12180ORGOOrganogenesis4.3079 of 5 stars$4.61+1.3%$7.50+62.7%+58.0%$577.84M$482.04M-32.93950TBPHTheravance Biopharma2.1859 of 5 stars$11.40-1.0%$21.33+87.1%+69.9%$576.02M$64.38M-9.66110 Related Companies and Tools Related Companies Day One Biopharmaceuticals Alternatives Autolus Therapeutics Alternatives KalVista Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Dianthus Therapeutics Alternatives Vir Biotechnology Alternatives AnaptysBio Alternatives Taysha Gene Therapies Alternatives Organogenesis Alternatives Theravance Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access